Wang, Linda
Smith-Salzberg, Bayle
Meyers, Kevin EC
Glenn, Dorey A.
Tuttle, Katherine R.
Derebail, Vimal K.
Brady, Tammy M.
Gibson, Keisha
Smith, Abigail R.
O’Shaughnessy, Michelle M.
Srivastava, Tarak
Hall, Gentzon
Zee, Jarcy
Bitzer, Markus
Sethna, Christine B.
Article History
Received: 9 August 2022
Accepted: 30 January 2023
First Online: 9 February 2023
Declarations
:
: The NEPTUNE protocol was approved by the Institutional Review Board at each participating site and informed consent/assent was obtained from participants. The analysis for this manuscript was considered exempt by the Institutional Review Board of Northwell Health. All methods were performed in accordance with the guidelines and regulations for human subjects research.
: CS was on an advisory board for Travere. VD was on advisory board for Travere and Bayer and is a consultant for Novartis. GH is a consultant for Reata Pharmaceuticals, Travere Pharmaceuticals, Otsuka Pharmaceuticals, Goldfinch Bio, Inc., Inside Edge Consulting and Third Bridge Consulting.
: All authors and NEPTUNE have consented to publication.